BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Advanced Research Projects Agency for Health (ARPA-H) has issued an Innovative Solutions Opening (ISO) for the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) Program. This solicitation seeks novel solutions to control protein folding and prevent aggregation, addressing chronic and degenerative diseases. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements. Solution Summaries are due March 4, 2026, and Full Proposals are due April 15, 2026.
Purpose & Scope
The BIOGAMI program aims to fundamentally transform therapeutic approaches to protein dysfunction. The core objective is to understand and control protein folding and aggregation, which are root causes of diseases like neurodegenerative disorders, cancers, and diabetes.
- Technical Area 1 (TA1): Focuses on establishing the "molecular grammar" of Intrinsically Disordered Regions (IDRs) through computational and experimental methods to characterize their behavior and structural ensembles.
- Technical Area 2 (TA2): Involves validating the foundational model from TA1 to develop detection and therapeutic applications. This includes methods to reverse aggregation, restore protein function, and identify early clinical indicators. Solutions should target one rare and one non-rare disease.
- Enabling Technologies: Proposers may leverage advanced biophysics, imaging, molecular dynamics, AI/ML, and high-throughput assays. Open sharing of deidentified/sanitized data from TA1 is required.
Contract Details
- Contract Type: Multiple Other Transaction (OT) Agreements.
- Period of Performance: Two phases: Phase 1 (0-24 months) and Phase 2 (25-48 months).
- Set-Aside: None specified. All responsible sources are eligible, including universities, non-profit organizations, small businesses, and other than small businesses. FFRDCs and Government entities are generally not permitted as performers, with specific exceptions. Proposers must be registered in SAM.gov.
Submission & Evaluation
The submission process is two-step:
- Solution Summary: Required first step, due March 4, 2026. Appendix A provides the format and instructions, including sections for concept summary, innovation, proposed work, team capabilities, and a Basis of Estimate (BOE). Solution summaries are limited to five pages.
- Full Proposal: Optional, by invitation based on Solution Summary review, due April 15, 2026. Appendix B details the three volumes: Technical and Management, Cost, and Administrative/Policy Requirements.
- Evaluation Criteria: Proposals will be assessed on:
- Overall Scientific and Technical Merit
- Proposer's Capabilities and/or Related Experience
- Potential Contribution to ARPA-H Mission and User Experience
- Assessment of Proposed Cost/Price
Key Requirements & Attachments
Proposers must review and adhere to numerous appendices for submission:
- Appendix G (Admin National Policy): Mandatory disclosures for OCI, IP, Research Security, HSR, ASR, Cybersecurity, Biosecurity.
- Appendix F (Cost Proposal Spreadsheet): Required template for detailed cost breakdowns.
- Appendix C (Task Description Document - TDD): Template for detailing tasks, subtasks, milestones, and deliverables.
- Appendix E (Data Management and Sharing Plan): Requirements for managing and sharing scientific data.
- Appendix H (Security Attestation Form): Certifications regarding Malign Foreign Talent Recruitment Programs.
- Appendix I (Dangerous Gain of Function Assessment): Assessment of risks related to gain-of-function research.
- Appendix J (Draft Other Transaction Agreement): Sample OTA for understanding contractual obligations.
Important Dates
- Questions & Answers Due: March 11, 2026
- Proposers' Day: February 20, 2026 (details in separate Special Notice ARPA-H-SN-26-147)
- Solution Summaries Due: March 4, 2026
- Full Proposals Due: April 15, 2026